PGEN: Precigen, Inc. Stock

by  •  • Comments Off on PGEN: Precigen, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 348.34
Enterprise Value ($M) 330.86
Book Value ($M) 97.02
Book Value / Share 0.38
Price / Book 3.59
NCAV ($M) 11.72
NCAV / Share 0.05
Price / NCAV 29.73

Profitability (mra)
Return on Invested Capital (ROIC) -0.93
Return on Assets (ROA) -0.40
Return on Equity (ROE) -0.53

Liquidity (mrq)
Quick Ratio 1.72
Current Ratio 1.72

Balance Sheet (mrq) ($M)
Current Assets 49.55
Assets 134.85
Liabilities 37.83
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 6.22
Operating Income -88.92
Net Income -95.90
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -66.93
Cash from Investing -3.09
Cash from Financing 29.59

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
05-03 13D/A Kirk Randal J 36.90 -3.16
02-27 13G/A Patient Capital Management, LLC 6.42 0.00
02-14 13G/A Ares Trading S.A. 8.30 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-04-29 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)
2024-03-19 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI
2023-11-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2023-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-20 111,795 350,730 31.87
2024-05-17 58,477 181,280 32.26
2024-05-16 171,567 137,869 124.44
2024-05-15 127,361 714,755 17.82

(click for more detail)

Similar Companies
PCRX – Pacira BioSciences, Inc. PCVX – Vaxcyte, Inc.
PEPG – PepGen Inc. PHAT – Phathom Pharmaceuticals, Inc.
PHVS – Pharvaris N.V.


Financial data and stock pages provided by
Fintel.io